Skip to content
Screener

Replimune Group REPL Total Operating Expenses

Total Operating Expenses at other companies

Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$16.28M+100%
Immunome logo
ImmunomeIMNM
$78.14M+54.7%
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$15.62M-8.1%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+195%
Enterprise value$967.91M+199%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026.

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805
Line itemThree Months Ended December 31, 2025Three Months Ended December 31, 2024Nine Months Ended December 31, 2025Nine Months Ended December 31, 2024
Operating expenses:
Research and development$53,140$48,004$168,860$135,472
Selling, general and administrative18,72818,01577,72146,827
Total operating expenses71,86866,019246,581182,299
Loss from operations(71,868)(66,019)(246,581)(182,299)
Other income (expense):
Research and development incentives3413761,1381,222
Investment income2,8465,13711,25615,243

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Replimune Group's total operating expenses?
Replimune Group (REPL) reported total operating expenses of $71.87M in Q4 2025.
How has Replimune Group's total operating expenses changed year-over-year?
Replimune Group's total operating expenses increased by 8.9% year-over-year, from $66.02M to $71.87M.
What is the long-term trend for Replimune Group's total operating expenses?
Over 3 years (2022 to 2025), Replimune Group's total operating expenses has grown at a 30.3% compound annual growth rate (CAGR), from $118.31M to $261.63M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Replimune Group's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude